This compound is a bis-protected imidazole-containing intermediate featuring two pyrrolidine rings each bearing a tert-butoxycarbonyl (Boc) protecting group. It is primarily utilized in the synthesis of compounds for hepatitis C virus (HCV) research.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 1007882-23-6
3-(4-Methoxy-phenoxy)-propylamine
pharmaceutical intermediate
4-chloro-2-methoxypyridine-3-carbaldehyde
pharmaceutical intermediate
2-Methoxy-4-methylpyridine
pharmaceutical intermediate
(S,Z)-(2-(5-((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethyl)diphenylphosphine oxide
Pharmaceutical intermediate for organic synthesis
Daclatasvir
active pharmaceutical ingredient
Daclatasvir dihydrochloride
active pharmaceutical ingredient
2-((2S)-Pyrrolidin-2-yl)-5-(4-(4-(2-((2S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)phenyl)phenyl)-1himidazole tetrahydrochloride
pharmaceutical intermediate
tert-butyl (2S)-2-[5-[4-[4-[2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
WPMTYMFNINZZHE-KYJUHHDHSA-N
CC(C)(C)OC(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)OC(C)(C)C